Path: ...!3.eu.feeder.erje.net!feeder.erje.net!feeder1.feed.ams11.usenet.farm!feed.usenet.farm!peer02.ams4!peer.am4.highwinds-media.com!news.highwinds-media.com!fx08.ams4.POSTED!not-for-mail
MIME-Version: 1.0
User-Agent: Mozilla Thunderbird
Newsgroups: fr.bio.medecine
Content-Language: fr
From: Paul Aubrin <paul.aubrin@invalid.org>
Subject: =?UTF-8?Q?=C3=89tude_RCT_sur_l=27efficacit=C3=A9_et_l=27innocuit?=
 =?UTF-8?Q?=C3=A9_de_l=27ivermectine?=
Content-Type: text/plain; charset=UTF-8; format=flowed
Content-Transfer-Encoding: 8bit
Lines: 16
Message-ID: <4p%6P.3856$GPW2.1260@fx08.ams4>
X-Complaints-To: abuse@eweka.nl
NNTP-Posting-Date: Fri, 13 Dec 2024 18:53:52 UTC
Organization: Eweka Internet Services
Bytes: 1221
Date: Fri, 13 Dec 2024 19:53:51 +0100
X-Received-Bytes: 1002
X-Original-Bytes: 951

Double aveugle et tout et tout....

https://clinicaltrials.gov/study/NCT05305560?tab=history&a=8#version-content-panel

Prophylaxie :
groupe traité : 30/200
groupe placebo : 105/199

https://www.cjoint.com/data/NLnsXFH1g8Z_prophyllaxie.png

Symptomes :
groupe traité : 28/200
groupe placé : 97/199

Le traitement par l'ivermectine était efficace et sûr.